When insurance is central
Ro’s $149 recurring monthly care membership excludes medication. Its $39 introductory offer and $74 monthly equivalent with annual prepayment describe different payment arrangements. If you are pursuing branded tirzepatide, ask who handles authorization and what you owe while the pharmacy price remains unresolved. Coverage assistance is a service, not a coverage guarantee.
When a menu contains several pathways
Mochi and Found list both branded and compounded options in the reviewed information. A low figure attached to one preparation cannot price another. Request a quote that identifies the actual prescription pathway. Mochi’s promotional membership language and medication floors should remain separate from the confirmed total for your proposed care.
Where Amble fits
Amble is included for readers comparing a compounded injection pathway. Its broader homepage starting prices do not establish a complete tirzepatide renewal bill. Ask for the exact preparation, dispensing pharmacy, supply period and refill cost. Compounded drugs are not FDA-approved; a shared ingredient does not make them interchangeable with approved medicines.
Compare a treatment change, too
Ask what happens financially if the clinician changes the prescription or stops treatment. A prepaid supply, an active membership and a pending pharmacy order can have different cancellation conditions. Save those terms with the quote. Do not infer that a clinical decision automatically refunds unused payments or ends a subscription.
Sources & comparison notes
By Peptide Routes, using public provider information. Promotional conditions and personal treatment totals remain subject to confirmation. We have not enrolled as patients or tested clinical care.
- Ro official treatment information
- FDA Foundayo approval
- Mochi Health official treatment information
- Found official treatment information
- Found current program overview
- Found detailed plan, billing and refund offer terms
- Amble official treatment information
- Amble program overview
- FDA concerns with unapproved GLP-1 drugs